A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers

Trial Profile

A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Bronchial cancer; Carcinoma; Cholangiocarcinoma; Duodenal cancer; Gallbladder cancer; Gastrointestinal cancer; Gynaecological cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 04 Apr 2017 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
    • 04 Apr 2017 Planned primary completion date changed from 1 Feb 2023 to 1 Aug 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top